| Literature DB >> 34367158 |
Laetitia Gay1, Cléa Melenotte1,2, Ines Lakbar3, Soraya Mezouar1, Christian Devaux1, Didier Raoult1, Marc-Karim Bendiane2, Marc Leone1,3, Jean-Louis Mège1.
Abstract
Epidemiological studies and clinical observations show evidence of sexual dimorphism in infectious diseases. Women are at less risk than men when it comes to developing most infectious diseases. However, understanding these observations requires a gender approach that takes into account an analysis of both biological and social factors. The host's response to infection differs in males and females because sex differences have an impact on hormonal and chromosomal control of immunity. Estradiol appears to confer protective immunity, while progesterone and testosterone suppress anti-infectious responses. In addition, genetic factors, including those associated with sex chromosomes, also affect susceptibility to infections. Finally, differences in occupational activities, lifestyle, and comorbidities play major roles in exposure to pathogens and management of diseases. Hence, considering sexual dimorphism as a critical variable for infectious diseases should be one of the steps taken toward developing personalized therapeutic approaches.Entities:
Keywords: gender; infectious disease; personalized medicine; sex hormones; sexual dimorphism
Mesh:
Year: 2021 PMID: 34367158 PMCID: PMC8339590 DOI: 10.3389/fimmu.2021.698121
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Multifactorial mechanisms of gender dimorphism.
Figure 2Effects of sex hormones on the immune system. Estrogens, progesterone, and androgens may directly affect immune cell functions. Generally, testosterone and progesterone are anti-inflammatory, suppressing several of the immune responses necessary for inflammation, whereas estradiol has bipotential effects: proinflammatory at low concentrations and anti-inflammatory at high concentrations. CCL, CC−chemokine ligand; CXCL, CXC-chemokine ligand; FASL, FAS ligand; iNOS, inducible nitric oxide synthase; ND, not defined; NO, nitric oxide; Treg, regulatory T.
Effect of sex hormones on diseases in animal models.
| Infections | Models | Susceptibility and severity | Hormonal effects | References | |
|---|---|---|---|---|---|
| Bacterial | C57BL/6 mice | M > F | ovariectomy: resistance lost | ( | |
| oestradiol treatment after ovariectomy: resistance restored | |||||
| Lewis rats | – | oestradiol treatment after ovariectomy: ↓susceptibility | ( | ||
| progesterone treatment after ovariectomy: ↑susceptibility | |||||
| Wistar rats | – | oestradiol treatment after ovariectomy: ↑protection against sepsis | ( | ||
| INS-GAS mice | M > F | oestradiol treatment: ↓severity of gastric lesions | ( | ||
| C57BL/6 mice | F > M | oestradiol treatment: ↓resistance by inhibiting IL-2 production and subsequent T cell proliferation | ( | ||
| DBA/2 mice | M > F | ovariectomy: ↑susceptibility | ( | ||
| oestradiol treatment: susceptibility mitigated | |||||
| BALB/c mice | M > F | castration: ↓severity | ( | ||
| BALB/c mice | M > F | testosterone treatment of female or castrated mice: ↑susceptibility | ( | ||
| Sprague-Dawley rats | M > F | ovariectomy: | ( | ||
| ↑mortality similar to males | |||||
| oestradiol treatment after gonadectomy of males and females: ameliorated the severity of disease | |||||
| Viral | Herpes simplex virus (HSV)-2 | C57BL/6 mice | – | progesterone treatment in females: ↑susceptibility | ( |
| ↓protective immune response | |||||
| oestradiol treatment: ↑protection | |||||
| Simian immunodeficiency virus (SIV) | Macaques | – | progesterone treatment: enhanced SIV vaginal transmission and disease course oestradiol treatment: protect against vaginal transmission of SIV | ( | |
| Parasitic | C57BL/6 mice | M > F | testosterone treatment in females: ↑severity | ( | |
| Syrian hamsters | castration: ↓severity | ||||
| gonadectomy: inhibition of amoebic liver abscess development | |||||
| Syrian hamsters | M > F | testosterone treatment in females: ↓severity | ( | ||
| C57BL/6 mice | M > F | testosterone treatment of females: ↑severity and mortality | ( | ||
| castration: resistance | |||||
| CBA/J mice | F > M | oestradiol treatment of males: ↑parasite load | ( | ||
| BALB/c mice | F > M | castration: ↑number of parasites | ( | ||
| ovariectomy: ↓number of parasites | |||||
| C57BL/6 mice | F > M | testosterone treatment in females: ↓severity and mortality | ( | ||
| oestradiol treatment of males: no effect | |||||
| castration: dissolves sex bias | |||||
| Fungal | CFW mice | more rapid clearance in females | gonadectomy: lower initial incidence of infection in females, but not in males in both sexes: ↑clearance of candiduria | ( | |
| C57BL/6 mice | M > F | oestradiol treatment after castration: ↓IL-10, ↓severity testosterone treatment after ovariectomy: ↑IL-10 | ( | ||
| ↗ clearance in females | |||||
Susceptibility to infection and the effects of sex hormones are described by comparing males (M) and females (F). The term ovariectomy is used only in the case of females, the term castration only for males and the term gonadectomy when it is used on males and females.
Infections that cause adverse pregnancy or foetal outcomes.
| Infections | Most at-risk trimester | Maternal clinical manifestations and severity | Maternal risk of mortality | Foetal risk | References | |
|---|---|---|---|---|---|---|
| Bacterial | 1st trimester | no specific clinical sign | yes | spontaneous abortion | ( | |
| preterm birth | ||||||
| congenital brucellosis | ||||||
| mortality | ||||||
| 2–3rd trimester | higher risk of persistent | yes | intrauterine growth restriction | ( | ||
| spontaneous abortion | ||||||
| preterm birth | ||||||
| foetal demise | ||||||
| 3rd trimester | sepsis, meningitis, rhombencephalitis | unknown | spontaneous abortion | ( | ||
| preterm birth | ||||||
| serious neonatal disease | ||||||
| foetal demise | ||||||
| all | no specific clinical sign | unknown | spontaneous abortion | ( | ||
| preterm birth | ||||||
| premature rupture of membranes | ||||||
| low birth weight | ||||||
| Group B | delivery | bacteraemia, sepsis pyelonephritis, | unknown | preterm birth | ( | |
| neonatal infection: sepsis, meningitis, pneumonia | ||||||
| Viral | Zika | 1st trimester | no specific clinical sign | unknown | microcephaly | ( |
| ocular abnormalities | ||||||
| foetal demise | ||||||
| Parvovirus B19 | 1st and 2nd trimesters | acute arthritis and arthralgias | unknown | spontaneous abortion | ( | |
| foetal complications (severe anaemia, hydrops fetalis) | ||||||
| Hepatitis B | 3rd trimester | no specific clinical sign | unknown | low birth weight | ( | |
| preterm birth | ||||||
| perinatal transmission | ||||||
| Hepatitis E | 3rd trimester | fulminant hepatic failure | yes | preterm birth | ( | |
| mortality | ||||||
| Herpes simplex virus | 3rd trimester | no specific clinical sign | unknown | spontaneous abortion | ( | |
| intrauterine growth restriction | ||||||
| congenital and neonatal herpes infections | ||||||
| Influenza virus | 3rd trimester | severe disease, pneumonia, cardiopulmonary event | yes | spontaneous abortion | ( | |
| preterm birth | ||||||
| mortality | ||||||
| Measles virus | 3rd trimester | severe disease, respiratory complications, pneumonia, encephalitis | yes | spontaneous abortion | ( | |
| preterm birth | ||||||
| congenital defects | ||||||
| Varicella virus | 3rd trimester | severe disease, pneumonia | yes | mortality | ( | |
| congenital varicella syndrome | ||||||
| CMV | all | no specific clinical sign | unknown | intrauterine growth restriction | ( | |
| congenital infection | ||||||
| mortality | ||||||
| Ebola virus | all | severe bleeding | yes | spontaneous abortion | ( | |
| preterm birth | ||||||
| Parasitic | first half of pregnancy | severe anaemia, renal failure, higher frequency of lymphadenopathy | yes | low birth weight | ( | |
| intrauterine growth restriction | ||||||
| preterm birth | ||||||
| 1st trimester | no specific clinical sign | unknown | congenital diseases (microcephaly, intracranial calcifications) | ( | ||
Infections that can cause adverse pregnancy or foetal outcomes and are described according to the stage of pregnancy.
Figure 3Hormone levels and immune responses during the menstrual cycle and pregnancy. Increased hormonal concentrations during pregnancy contribute to the immune shifts to support a successful pregnancy but also increase the susceptibility of women to infectious disease.
Genetic susceptibility to infections in mice.
| Infections | Genetic variation | Effect of genetic variation | References |
|---|---|---|---|
| Influenza A virus | chromosome Y | ↗ susceptibility to infection of males | ( |
| ↗ pathogenic immune responses in lungs | |||
| Coxsackievirus B3 | chromosome Y | ↗ mortality in infected males | ( |
| Char 1-4 | greater resistance of females (Char 2, Char 4) | ( | |
| Scl-2 | greater resistance of females | ( | |
| Mousepox | Rmp1–4 | greater resistance of females (Rmp 2, Rmp 4) | ( |
Genetic variations in the Y chromosome influence the survival of male mice following influenza A virus and coxsackievirus B3 infection. Resistance genes have been identified, and the effects of these genes confer greater resistance to infections for female mice.
Figure 4Infection prevalence according to anatomical characteristics. Data extracted from a long-term cohort followed in our institution.
Figure 5Sex differences in the prevalence of infections. The male-to-female (M/F) ratios for different (A) bacterial, (B) parasitic and fungal, and (C) viral infections are presented. T. whipplei infection occurs in six men for every one woman, but prevalence is similar between men and women for Toxoplasma gondii infection, whereas anal HPV infections are more frequent in women. Data extracted from (111).
Figure 6Percentage of patients with persistent C. burnetii infection regarding sex and age. The proportion of men and women patients for (A) all persistent C. burnetii infections, (B) C. burnetii endocarditis, and (C) vascular C. burnetii infections are presented. In children, persistent C. burnetii infection affects girls and boys similarly, whereas adult men are mostly affected. After 40 years of age, men represent more than 70% of patients.
Figure 7Percentage of cancer cases attributable to infectious agents by sex. Sex disparities are observed in infection-associated cancers. Globally, men are more likely to develop cancer because of infection, except in a few cases, such as HPV infection.